loading page

The first dose of Sinopharm vaccine in the elderly with Parkinson's disease was associated with death within the first 24 hours
  • +1
  • Pooya Jalali,
  • Sahar Taher,
  • Mehdi Khanbabayi Gol,
  • Khalil Ansarin
Pooya Jalali
Islamic Azad University Tabriz Branch
Author Profile
Sahar Taher
Islamic Azad University Tabriz Branch
Author Profile
Mehdi Khanbabayi Gol
Tabriz University of Medical Sciences
Author Profile
Khalil Ansarin
Tabriz University of Medical Sciences
Author Profile

Abstract

Severe Acute Respiratory Coronavirus Syndrome 2 (SARS-CoV-2) is a new human coronavirus family discovered during the highly communicable respiratory disease outbreak in Wuhan, China, in 2019. Various COVID-19 vaccines are up to 95% effective against symptomatic infections caused by the COVID-19. Whether people with PD or PS have an increased risk of COVID-19 and are associated with a higher risk of death is still uncertain. In this study, we report eleven cases of PD patients who died whitin 24 hours after vaccination with the Sinopharm. All patients were over 79 years old (84.64 ± 5.08). All patients were SARS-CoV2 PCR negative and took their first dose of the Sinopharm. All patients had a duration of more than 5 years with PD. All patients presented to the hospital less than 12 hours after vaccination. All patients died less than 24 hours after vaccination. In this study, All the patients were elderly and hypertension and diabetes were seen in 11 (100%) and 7 (63.6%) patients which could reinforce the hypothesis that older patients with PD should be vaccinated more cautiously and these patients should be discussed the vaccine with their physician especially in patients who have other comorbidities. Because our report was a case series study, we only identified patients, and the causality could not be assumed or proven.
18 Jul 2022Submitted to British Journal of Clinical Pharmacology
11 Aug 2022Assigned to Editor
11 Aug 2022Submission Checks Completed
15 Aug 2022Reviewer(s) Assigned